Search

everythinglearnresearchcommunity

for

Search:↓

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Less differentiated melanoma cells are more vulnerable to a type of cell death, which could improve cancer treatments.

Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.

A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.

Microneedling and oral tranexamic acid both improve facial melasma, but microneedling shows more sustained benefits.

Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

The scaffold effectively prevents melanoma relapse and aids wound healing.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

New steroid derivatives show promise as anticancer agents, even against resistant cells.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

The treatment combination is effective and generally safe for lung cancer.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Two people lost hair unexpectedly after getting a common hair loss treatment with a drug called Dutasteride.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

Lasers can help reduce skin side effects from cancer treatment.

A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.